Literature DB >> 2144427

PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system.

K Wienhard1, H H Coenen, G Pawlik, J Rudolf, P Laufer, S Jovkar, G Stöcklin, W D Heiss.   

Abstract

PET studies of dopamine D2-receptor binding were performed in thirty patients with various disorders related to the dopaminergic system and in six healthy controls. Uptake of [18F]fluoroethylspiperone in caudate over three hours was analyzed in terms of several indices of receptor binding:caudate-to-cerebellum activity ratio, concentration of ligand as percentage of injected dose, caudate-to-blood radioactivity ratio, slope of tracer uptake curves, binding potential, kinetic constants of a three compartment model. In 14 patients brain glucose metabolism was also measured. Data on medicated patients demonstrate that the average values of most of the above parameters indicate the decreased number of available D2-receptors whereby, besides an age dependent decline, the caudate-to-cerebellum ratio affords the relatively best distinction among diagnostic groups. In individual cases, large variability among subjects permits only the classification of severe pathologies. Morphological damage and neuronal loss in the striatum may also cause abnormal low values both for the indices of receptor binding and for glucose consumption, thus providing a possible pathogenetic link between receptor dysfunction and impaired energy metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144427     DOI: 10.1007/bf01245042

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  29 in total

1.  In vivo [3H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization.

Authors:  D C Chugani; R F Ackermann; M E Phelps
Journal:  J Cereb Blood Flow Metab       Date:  1988-06       Impact factor: 6.200

2.  Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.

Authors:  M Smith; A P Wolf; J D Brodie; C D Arnett; F Barouche; C Y Shiue; J S Fowler; J A Russell; R R MacGregor; A Wolkin
Journal:  Biol Psychiatry       Date:  1988-04-01       Impact factor: 13.382

3.  Estimation of local cerebral glucose utilization by positron emission tomography of [18F]2-fluoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures.

Authors:  K Wienhard; G Pawlik; K Herholz; R Wagner; W D Heiss
Journal:  J Cereb Blood Flow Metab       Date:  1985-03       Impact factor: 6.200

Review 4.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

5.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.

Authors:  B Bokobza; M Ruberg; B Scatton; F Javoy-Agid; Y Agid
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

6.  Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens.

Authors:  D O Kiesewetter; W C Eckelman; R M Cohen; R D Finn; S M Larson
Journal:  Int J Rad Appl Instrum A       Date:  1986

7.  Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose.

Authors:  W D Heiss; G Pawlik; K Herholz; R Wagner; H Göldner; K Wienhard
Journal:  J Cereb Blood Flow Metab       Date:  1984-06       Impact factor: 6.200

8.  No-carrier-added 3-(2'-[18F]fluoroethyl)spiperone, a new dopamine receptor-binding tracer for positron emission tomography.

Authors:  N Satyamurthy; G T Bida; J R Barrio; A Luxen; J C Mazziotta; S C Huang; M E Phelps
Journal:  Int J Rad Appl Instrum B       Date:  1986

9.  Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.

Authors:  D E Kuhl; M E Phelps; C H Markham; E J Metter; W H Riege; J Winter
Journal:  Ann Neurol       Date:  1982-11       Impact factor: 10.422

10.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.

Authors:  D F Wong; H N Wagner; L E Tune; R F Dannals; G D Pearlson; J M Links; C A Tamminga; E P Broussolle; H T Ravert; A A Wilson; J K Toung; J Malat; J A Williams; L A O'Tuama; S H Snyder; M J Kuhar; A Gjedde
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

View more
  8 in total

Review 1.  Structural and functional brain imaging in schizophrenia.

Authors:  J M Cleghorn; R B Zipursky; S J List
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

Review 2.  PET molecular imaging in stem cell therapy for neurological diseases.

Authors:  Jiachuan Wang; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-23       Impact factor: 9.236

3.  Effect of tissue heterogeneity on quantification in positron emission tomography.

Authors:  G Blomqvist; A A Lammertsma; B Mazoyer; K Wienhard
Journal:  Eur J Nucl Med       Date:  1995-07

Review 4.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

Review 5.  [Positron emission tomography in neuroscience. An integrative part of clinical diagnostic methods and experimental research].

Authors:  B Schaller
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

6.  Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.

Authors:  G Schlaug; H Hefter; B Nebeling; V Engelbrecht; P Weiss; G Stöcklin; R J Seitz
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

7.  Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol.

Authors:  H Karbe; K Wienhard; K Hamacher; M Huber; K Herholz; H H Coenen; G Stöcklin; A Lövenich; W D Heiss
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson disease.

Authors:  D Giobbe; G C Castellano; V Podio
Journal:  Ital J Neurol Sci       Date:  1993-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.